Rocket Pharmaceuticals (RCKT)
(Real Time Quote from BATS)
$21.83 USD
+0.38 (1.77%)
Updated May 31, 2024 10:43 AM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
RCKT 21.83 +0.38(1.77%)
Will RCKT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RCKT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RCKT
Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why
RCKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia
Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report?
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4
Other News for RCKT
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
Rocket Pharmaceuticals granted orphan product designation for RP-A601 by EC
Buy Rating on Rocket Pharmaceuticals Amidst Positive Outlook and Strategic Execution
Cantor picks 14 undervalued biotech stocks worth a second look
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)